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response to pneumococcal vaccine
in children with transient hypo-
gammaglobulinemia of infancyFIG 1. Median IgM (A), IgA (B), and IgG (C) anti-PCP antibodies in HC (white
bars) and children with UH (black bars) before (pre) and 4 weeks after each
PV dose (post-I, post-II, and post-III). *P values <.05. The continuous line
compares pre- and postvaccination titers within the same cohort. The
dotted line compares postvaccination titers between HC and children
with UH.To the Editor:
Transient hypogammaglobulinemia of infancy (THI) is a
primary antibody deficiency occurring in the first years of life
and is characterized by a delay in the immunoglobulin production
that spontaneously recovers in early infancy. In the young
symptomatic child with low IgG levels and more than 2% B
cells, there are no peculiar clinical and immunologic features that
allow discrimination between self-limiting THI, common vari-
able immunodeficiency, or other dysgammaglobulinemias. Only
those patients whose IgG levels have normalized after age 4 years
have a definitive THI diagnosis made a posteriori.1,2
In a previous study, we demonstrated that a subgroup of
children with putative THI shares abnormalities of B-cell
memory subsets with other defined immune deficiencies, and
cautiously suggested the term ‘‘hypogammaglobulinemia during
infancy’’ to define conditions in which it is not yet possible to
discriminate THI from other primary antibody defects.3 Recently,
according to the new European Society for Immunodeficiencies
diagnostic criteria, a working definition of ‘‘unclassified hypo-
gammaglobulinemia’’ (UH) has been introduced to register pa-
tients with IgG values below age-related normal values detected
in the first 3 years of life that will be moved to THI diagnosis if
there is spontaneous resolution before age 4 years (http://esid.
org/Working-Parties/Registry/Diagnosis-criteria).
Measurement of pneumococcal antibodies is an important tool
in the immunologic assessment of patients with suspected
immune deficiencies.4
The aim of this study was to analyze prospectively IgM-, IgA-,
and IgG-antibody responses to pneumococcus vaccine (PV) in
children with UH until THI or other immune deficiencies criteria
were met.In the context of the Italian Primary Immunodeficiency
Network, we enrolled 21 patients (age range, 12-36 months)
with a history of recurrent infections who had an initial diagnosis
of UH in accordance with our national protocol for THI (http://
www.aieop.org/stdoc/prot/rec_thi_en_06.pdf) and monitored
them until age 4 years with regular clinical and immunologic
evaluations. Eighteen healthy age-matched children (HC) (age
range, 15-40 months) were used as controls. Informed consent
was obtained from the patient’s parents. The Institutional Ethical
Committee approved the study. All patients and HC received 3
doses of 7-valent conjugated pneumococcus vaccine (PCV 7, Pre-
vnar, Pfizer), with the exception of 5 children with UH and 6 HC
who received the third PV dosewith unconjugated pneumococcus
polyvalent vaccine (Pneumo23; Aventis, Milan, Italy) because
they were older than 2 years. Serum samples were collected
from children with UH and HC before and 4 weeks after each
FIG 2. Pneumococcal IgM, IgA, and IgG kinetics at time of pre, post-I, post-
II, post-III and months after the completion of the primary immunization
series in patient 1 with UH (A) and in patient 2 with common variable immu-
nodeficiency (B). The left axis refers to IgA and IgM values (U/mL), and the
right axis refers to IgG values (mg/L). Pneumococcal polysaccharide IgM
(dotted line with black diamond), IgA (dashed line with black squares),
and IgG (continuous line with black triangles) are shown.
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pneumococcal capsular polysaccharide (PCP) antibodies, anti–
polyribosyl-ribitol phosphate antibodies (specific to Hib), and
anti–tetanus toxoid by ELISA (The Binding Site, Birmingham,
United Kingdom: VaccZyme Anti-PCP IgG Enzyme Immuno-
assay; Anti-PCP IgA and Anti-PCP IgM EIA kit; VaccZyme Hu-
man Anti-Hib Enzyme Immunoassay; VaccZyme Tetanus toxoid
IgG).5 Group comparisons were performed using the Mann-
Whitney test. Data are presented as median. P values of less
than .05 were considered statistically significant. Statistical anal-
ysis was performed using Statistical Analysis Software.
Data of IgM, IgA, and IgG anti-PCP in HC are reported in
Fig 1, A-C. The median level of IgM anti-PCP increased from 85
U/mL before vaccination to 366 U/mL (P 5 .028) after the first
dose. This 4-fold increase was followed by a titer decline to pre-
vaccination values after the second and third doses (87 and 69 U/
mL, respectively). The median level of IgA anti-PCP prevaccina-
tion titer reached a more than 10-fold increase after the first dose
(from 10 U/mL to 115 U/mL; P5 .018) and then decreased to 50
and 27 U/mL after the second (P 5 .015) and third dose, respec-
tively. The median level of IgG anti-PCP showed a more than 10-
fold increase after the first dose (from 14 mg/L to 154 mg/L;P 5 .018). The post-I titer was stable at the post-II evaluation
(164 mg/L; P 5 .008) and approximately halved at the post-III
evaluation (78 mg/L in children who received 3 doses of PCV 7
and 111 mg/L in children who received the third PV dosewith un-
conjugated PV vaccine because theywere older than 2 years). The
post-III titer maintained a more than 4-fold concentration in com-
parison to prevaccination titers independently of the type of vac-
cine used for the third immunization (pre vs post-III: P 5 .01 for
PCV7; P5 .006 for unconjugated PV). Thus, HC showed a tran-
sient IgM response and a persistent IgG response. Of interest was
the finding of a strong initial specific IgA response followed by a
rapid decline, suggesting an impaired capacity in the first years of
life to maintain IgA-mediated memory responses.
IgM, IgA, and IgG anti-PCP in children with UH showed a
completely different pattern. As shown in Fig 1, A-C, poor spe-
cific anti-PCP responses were generally observed. The median
IgM anti-PCP levels after each PV dose did not show any sig-
nificant increase in children with UH (from a prevaccination
titer of 35 U/mL to 41 U/mL [post-I], 67 U/mL [post-II],
and 54 U/mL [post-III]). The IgA anti-PCP response was
generally very low (from a prevaccination median titer of 2
U/mL to 7 U/mL [post-I], 3 U/mL [post-II], and 4 U/mL
[post-III]). The IgG anti-PCP response was low (from a me-
dian prevaccination titer of 4 mg/L to 19 mg/L [post-I],
28 mg/L [post-II], and 21 mg/L in children who received 3
doses of PCV 7 and 46 mg/L in children who received uncon-
jugated pneumococcus polyvalent as the third dose because
they were older than 3 years [post-III]).
All except 1 child with UH responded to tetanus toxoid
vaccination (median, 1 IU/mL). All children with UH responded
to Hib vaccine (median, 1.75 mg/L). B-cell subsets were similar
to those already reported in THI children3—CD272IgM1IgD1:
84.6% 6 5.7%; CD271IgM1IgD1: 8.8% 6 3%; CD271
IgM2IgD2: 4.8% 6 3.1%; CD3811IgM11: 11.5% 6 5.3%.
About 90% (19 of 21) of the children with UH normalized
their serum total IgG values, within age 22 months, allowing the
diagnosis of THI. Conversely, 2 of 21 continued to suffer from
recurrent respiratory infections and showed a persistent condi-
tion of hypogammaglobulinemia after the fourth year of life.
One patient (no. 1) maintained the diagnosis of UH, owing to a
marked decrease in IgG level with normal antibody responses.
One patient (no. 2) met the criteria for common variable
immunodeficiency diagnosis, owing to a marked decrease in
IgG (495 mg/dL; age-matched healthy donors, 528-1312 mg/
dL) and IgA (23 mg/dL) levels, poor antibody response to
vaccines, and low switched memory B cells (2.7%). In this
patient, we identified a heterozygous C104R variant in the
TNFRSF13B gene encoding the transmembrane activator and
calcium modulator and cyclophilin ligand interactor.
In the 2 patients who did not normalize total IgG levels at age
more than 4 years, we prospectively monitored IgM, IgA, and IgG
anti-PCP after the completion of the primary vaccination series
for a period of 54 months in patient 1 and for a period of
24months in patient 2. As shown in Fig 2,A, in patient 1, anti-PCP
IgM, IgA, and IgG levels declined over time from the completion
of the cycle of immunization and then increased, with a peak at
46 months, when an acute infection, caused by Streptococcus
pneumoniae, occurred. In patient 2, anti-PCP IgG and IgA re-
sponses were almost undetectable over timewhereas only specific
IgM antibodies were evident (Fig 2, B).
J ALLERGY CLIN IMMUNOL
VOLUME 137, NUMBER 2
LETTERS TO THE EDITOR 619According to a recent JeffreyModell Foundation survey, THI is
generally listed within the top 10 more prevalent primary
immunodeficiency disorders worldwide and as the most
frequently reported in Eastern Europe.6 Although its outcome is
considered benign, the psychological impact of this condition,
due to patient’s age and frustrating uncertainty on the long-term
outlook, is greater than expected.7
In this study, although preliminary for the cohort size and the
potential bias of age and vaccination schedule, we demonstrated
that children with THI showed an abnormal anti-PCP response.
Consistent with our previous report, a further tile is added to
B-cell memory defect and immunoglobulin defect.
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micking Mendelian susceptibility
to mycobacterial disease in a
patient with signal transducer
and activator of transcription 1
(STAT1) gain-of-function mutationTo the Editor:
Signal transducer and activator of transcription 1 (STAT1)
mutations cause several rare primary immunodeficiencies.1
Chronic mucocutaneous candidiasis disease (CMCD) ischaracterized by persistent or recurrent skin, nail, and mucosal
membrane infections caused by Candida albicans. Patients
with Mendelian susceptibility to mycobacterial disease
(MSMD) suffer from atypical mycobacterial infections or se-
vere tuberculosis infections. The gain-of-function STAT1 mu-
tations cause an autosomal-dominant form of CMCD,2
whereas the loss-of-function STAT1 alleles cause MSMD.3
Furthermore, STAT1 mutations are associated with severe-
lethal clinical phenotypes4 or even autoimmune/immune dys-
regulation phenotypes.5
Herewe report the case of an 18-year-oldman with the gain-of-
function STAT1 mutation who presented severe tuberculosis
infection mimicking MSMD. The identical gain-of-function
STAT1mutation was found in his mother, who developed gingival
squamous cell carcinoma.
The proband was admitted to a general hospital because of high
fever and a 1-month history of worsening left-sided abdominal
pain. His medical history was unremarkable apart from recurrent
cutaneous candidiasis on the sole of his right foot (Fig 1, A). He
had received a BCG vaccination without any complication.
A contrast-enhanced computed tomography scan identified an
infiltration in the left lower lobe of his lung and multiple enlarged
intestinal lymph nodes with calcification in the abdomen (Fig 1,
B). No pathogenic bacteriumwas detected in his sputum, whereas
Mycobacterium tuberculosis was detected on the culture of
gastric aspirate specimens andwas confirmed by PCR. The patho-
logical examination of his duodenal mucosa revealed histiocyte
aggregation (Fig 1, C), and subsequent Ziehl-Neelsen staining
detected acid-fast bacilli. His tuberculous lymphadenitis res-
ponded well to triple therapy (rifampicin, isoniazid, and etham-
butol). However, before and during the treatment, repeated
QuantiFERON-TB test results (Cellestis Limited, Carnegie,
Victoria, Australia) were negative. Tuberculin skin test results
(2.5 TU) were also negative even after the completion of therapy.
Therefore, congenital cellular immune defects were suspected
and he was referred to our hospital.
His total lymphocyte (0.93 109/L) and CD41 lymphocyte (0.3
3 109/L) counts were decreased, but the proliferative responses
for concavalin A and phytohemagglutinin were normal. With pa-
tient’s written informed consent, we sequenced 6 genes associated
with MSMD. Unexpectedly, we identified a heterozygous gain-
of-function STAT1 mutation that was associated with CMCD
(c.821G>A, p.Arg274Gln) (Fig 2, A and B). Subsequent analysis
revealed enhanced STAT1 phosphorylation in response to IFN-g
and resistance to staurosporine-driven dephosphorylation, which
is a characteristic of CMCD (Fig 2, C; see Fig E1 in this article’s
Online Repository at www.jacionline.org).6 We confirmed that
the antimicrobial activity of the patient’s macrophages against
Mycobacterium avium was decreased compared with that in
healthy volunteers (Fig 2, D).
A familial genetic study identified the identical gain-
of-function STAT1 mutation in his mother (c.821G>A,
p.Arg274Gln) (Fig 2, A andB). She had no history of heavy drink-
ing or smoking. She had suffered from chronic bronchiectasis
and oral candidiasis (Fig 1, D) for several decades. At the age
of 44 years, she developed esophageal intraepithelial neoplasia
and lower gingival squamous cell carcinoma (Fig 1,D-F). She un-
derwent surgical tumor resection, subtotal esophagectomy, and
esophagogastric anastomosis.
A few cases of patients with CMCD with a mycobacterium
infection are reported. Sampaio et al7 reported a patient who
